Scholarlink

<p>Carbamoyl-phosphate synthetase II/Aspartate transcarbamylase/Dihydroorotase (CAD) is a multifunctional enzyme with demonstrated oncogenic potential across various cancers, emerging as a promising therapeutic target. However, its functional role and therapeutic relevance in colorectal cancer (CRC) remain unclear. Here, we demonstrate for the first time that elevated CAD expression promotes CRC malignancy by enhancing proliferation, motility, and apoptosis resistance. Clinically, high CAD expression correlates with poor survival in CRC patients. Leveraging these findings, we developed a tumor microenvironment (TME)-responsive nickel‑copper nano‑heterojunction (NCSH@siCAD&amp;AVT‑18A) that selectively releases hydrogen sulfide and copper ions in the acidic, reducing TME. This platform induces intracellular acidification and redox stress, leading to synergistic tumor suppression through a&#xa0;trimodal strategy that integrates CAD gene silencing, cuproptosis induction, and immune modulation. In vivo studies confirmed potent antitumor efficacy across subcutaneous, orthotopic, and metastatic CRC models, without systemic toxicity. Our work identifies CAD as a key prognostic marker and therapeutic target in CRC, and presents a novel combinatory regimen that integrates gene silencing with metal ion-mediated therapy, offering a mechanistically innovative and clinically viable strategy for CRC treatment with superior efficacy and minimal toxicity.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal cancer progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Yuanchu Xiang,
  • Yujie Liao,
  • Mi Yao,
  • Zihang Zhai,
  • Wenbo Zhao,
  • Yongxing Zhang,
  • Zongpeng Chen,
  • Chang Li,
  • Ximei Wang,
  • Shiye Zhang,
  • Shanni Li,
  • Lipeng Zhu,
  • Jie Chen,
  • Weidong Liu,
  • Zanxian Xia,
  • Jian Peng

摘要

Carbamoyl-phosphate synthetase II/Aspartate transcarbamylase/Dihydroorotase (CAD) is a multifunctional enzyme with demonstrated oncogenic potential across various cancers, emerging as a promising therapeutic target. However, its functional role and therapeutic relevance in colorectal cancer (CRC) remain unclear. Here, we demonstrate for the first time that elevated CAD expression promotes CRC malignancy by enhancing proliferation, motility, and apoptosis resistance. Clinically, high CAD expression correlates with poor survival in CRC patients. Leveraging these findings, we developed a tumor microenvironment (TME)-responsive nickel‑copper nano‑heterojunction (NCSH@siCAD&AVT‑18A) that selectively releases hydrogen sulfide and copper ions in the acidic, reducing TME. This platform induces intracellular acidification and redox stress, leading to synergistic tumor suppression through a trimodal strategy that integrates CAD gene silencing, cuproptosis induction, and immune modulation. In vivo studies confirmed potent antitumor efficacy across subcutaneous, orthotopic, and metastatic CRC models, without systemic toxicity. Our work identifies CAD as a key prognostic marker and therapeutic target in CRC, and presents a novel combinatory regimen that integrates gene silencing with metal ion-mediated therapy, offering a mechanistically innovative and clinically viable strategy for CRC treatment with superior efficacy and minimal toxicity.

Graphical abstract